[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Screen on your Watchlists and Portfolios with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Abbvie Inc (ABBV)

Abbvie Inc (ABBV)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 382,492,992
  • Shares Outstanding, K 1,766,793
  • Annual Sales, $ 61,160 M
  • Annual Income, $ 4,226 M
  • EBIT $ 15,332 M
  • EBITDA $ 24,318 M
  • 60-Month Beta 0.32
  • Price/Sales 6.39
  • Price/Cash Flow 14.61
  • Price/Book N/A

Options Overview Details

View History
  • Implied Volatility 27.27% (+0.57%)
  • Historical Volatility 22.25%
  • IV Percentile 49%
  • IV Rank 52.34%
  • IV High 35.30% on 04/27/26
  • IV Low 18.46% on 08/22/25
  • Expected Move (DTE 7) 5.77 (2.67%)
  • Put/Call Vol Ratio 0.45
  • Today's Volume 14,596
  • Volume Avg (30-Day) 13,864
  • Put/Call OI Ratio 0.84
  • Today's Open Interest 274,299
  • Open Int (30-Day) 252,867
  • Expected Range 210.72 to 222.26

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 32 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $3.78
  • Number of Estimates 7
  • High Estimate $3.93
  • Low Estimate $3.72
  • Prior Year $2.97
  • Growth Rate Est. (year over year) +27.27%

Price Performance

See More
Period Period Low Period High Performance
1-Month
208.73 +3.72%
on 05/19/26
230.47 -6.07%
on 06/05/26
+7.08 (+3.38%)
since 05/18/26
3-Month
190.75 +13.49%
on 04/29/26
230.47 -6.07%
on 06/05/26
+8.15 (+3.91%)
since 03/18/26
52-Week
181.73 +19.13%
on 06/27/25
244.81 -11.57%
on 10/01/25
+31.00 (+16.71%)
since 06/18/25

Most Recent Stories

More News
AbbVie Declares Quarterly Dividend

NORTH CHICAGO, Ill. , June 18, 2026 /PRNewswire/ -- The board of directors of AbbVie Inc. (NYSE: ABBV) today declared a quarterly cash dividend of $1.73 per share. 

ABBV : 216.49 (-2.14%)
Allergan Aesthetics Receives U.S. FDA Approval for SKINVIVE by JUVÉDERM® for the Improvement of Neck Appearance

IRVINE, Calif. , June 16, 2026 /PRNewswire/ -- Allergan Aesthetics, an AbbVie company (NYSE: ABBV), today announced the U.S. Food and Drug Administration (FDA) approval of SKINVIVE by JUVÉDERM...

ABBV : 216.49 (-2.14%)
AbbVie Presents New Data at EHA 2026 Congress for VENCLEXTA®/VENCLYXTO® (venetoclax) in First-Line Chronic Lymphocytic Leukemia Highlighting Long-Term Treatment Outcomes for Patients: Nine-Year Results

NORTH CHICAGO, Ill. , June 12, 2026 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced new Phase 3 data on a fixed-duration venetoclax-based combination at the European Hematology Association (EHA)...

ABBV : 216.49 (-2.14%)
Allergan Aesthetics Releases 'The Aesthetics Evolution: What Consumers Really Want' Highlighting Consumer Motivations and Expectations in Aesthetics

IRVINE, Calif. , June 10, 2026 /PRNewswire/ -- Allergan Aesthetics, an AbbVie company, today announced the release of What Consumers Really Want , the latest installment in The Aesthetics Evolution...

ABBV : 216.49 (-2.14%)
AbbVie Presents New Data Across Its Blood Cancer Portfolio at EHA 2026

NORTH CHICAGO, Ill. , June 8, 2026 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced it will share new data at the European Hematology Association (EHA) 2026 Congress and will showcase clinical...

ABBV : 216.49 (-2.14%)
AbbVie Stock: Is ABBV Outperforming the Healthcare Sector?

AbbVie has underperformed the healthcare sector, and analysts remain somewhat optimistic about the stock’s outlook.

XLV : 149.40 (-0.87%)
JNJ : 228.39 (-2.48%)
ABBV : 216.49 (-2.14%)
AbbVie Announces European Commission Authorization of Expanded Label for VENCLYXTO® (venetoclax) to Include Additional Combinations in Previously Untreated Chronic Lymphocytic Leukemia

NORTH CHICAGO, Ill. , May 29, 2026 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that the European Commission (EC) has authorized an expanded label for VENCLYXTO ® (venetoclax) to include...

ABBV : 216.49 (-2.14%)
Hims & Hers Eyes Global Growth: Will $1.15B Eucalyptus Deal Fuel Its Recovery or Dilute Shareholders?

Hims & Hers is acquiring Australian telehealth platform Eucalyptus as part of its international expansion plan while using $350 million in convertible senior notes.

HIMS : 35.47 (+11.23%)
NVO : 43.19 (-0.76%)
LLY : 1,098.57 (-1.21%)
ABBV : 216.49 (-2.14%)
U.S. FDA Approves DECNUPAZTM (pivekimab sunirine-pvzy) for Treatment of Adult Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm, an Ultra-Rare and Aggressive Blood Cancer With Limited Treatment Options

- DECNUPAZ is the first and only antibody-drug conjugate (ADC) approved for blastic plasmacytoid dendritic cell neoplasm (BPDCN) that is initiated in an outpatient setting - DECNUPAZ...

ABBV : 216.49 (-2.14%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Sell with a Weakest short term outlook on maintaining the current direction.

Relative Strength just crossed below 50%. The market is indicating support for a bearish trend.

See More Share

Business Summary

AbbVie has become one of the top-most pharma companies after it acquired Allergan. The deal has transformed AbbVie's portfolio by lowering its dependence on Humira, its flagship product. AbbVie has one of the most popular cancer drugs in its portfolio, Imbruvica and its newest immunology drugs Skyrizi...

See More

Key Turning Points

3rd Resistance Point 227.75
2nd Resistance Point 225.05
1st Resistance Point 220.77
Last Price 216.49
1st Support Level 213.79
2nd Support Level 211.09
3rd Support Level 206.81

See More

52-Week High 244.81
Fibonacci 61.8% 220.71
Last Price 216.49
Fibonacci 50% 213.27
Fibonacci 38.2% 205.83
52-Week Low 181.73

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.